Intellectual Property and Recognition - In 2023, Shanxi Dayu Bioengineering obtained two invention patents: one for glucose oxidase and its preparation method, and another for a high-density culture method of Pichia pastoris[5]. - The company was recognized as a "2023 Typical Case of IoT Empowering Industry Development" by the Ministry of Industry and Information Technology in August 2023[6]. - In November 2023, the company was awarded the title of "National Intellectual Property Advantage Enterprise" by the National Intellectual Property Administration[7]. - Shanxi Dayu Bioengineering was recognized as a "Demonstration Enterprise of Technological Innovation" by the Shanxi Provincial Department of Industry and Information Technology in October 2023[9]. - The company was awarded the title of "Specialized, Refined, and New Small and Medium-sized Enterprise" by the Shanxi Provincial Small Enterprise Development Promotion Bureau in July 2023[8]. - The total number of patents owned by the company increased to 33 from 31 in the previous period, with invention patents rising to 14 from 12[84]. - The company has been recognized as a high-tech enterprise, benefiting from a reduced corporate income tax rate of 15% for three years[77]. - The company has not reported any significant defects in its internal management systems during the reporting period[166]. Financial Performance - The company's operating revenue for 2023 was approximately ¥160.58 million, representing a year-over-year increase of 2.29% compared to ¥156.98 million in 2022[30]. - The net profit attributable to shareholders of the listed company was approximately -¥2.09 million, a significant decline of 111.52% from ¥18.15 million in 2022[30]. - The gross profit margin decreased to 27.28% in 2023 from 43.80% in 2022[30]. - Total assets at the end of 2023 were approximately ¥423.71 million, down 2.22% from ¥433.32 million at the end of 2022[32]. - Total liabilities increased by 41.61% to approximately ¥106.40 million in 2023 from ¥75.14 million in 2022[32]. - The weighted average return on equity (ROE) based on net profit was -0.62% in 2023, down from 6.07% in 2022[30]. - The net cash flow from operating activities decreased by 71.12% to approximately ¥7.68 million in 2023 from ¥26.60 million in 2022[33]. - The company reported a basic earnings per share of -¥0.02 in 2023, a decline of 105.41% from ¥0.37 in 2022[30]. - The company achieved revenue of 160.58 million yuan, a year-on-year increase of 2.29%, while net profit attributable to shareholders was -2.09 million yuan, a decline of 111.52%[45]. - Total assets amounted to 423.71 million yuan, a decrease of 2.22% compared to the end of the previous year, while total liabilities increased by 41.61% to 106.40 million yuan[45]. - The company reported a significant decrease in cash and cash equivalents by 56.11% to 198.01 million yuan due to the cash dividend payout[51]. - The company reported a significant increase in financial expenses, rising by 617.33% to ¥1,982,084.82, attributed to higher short-term borrowing costs[55][59]. - The company’s main business income rose by 2.52% to ¥157,300,103.00, while other business income decreased by 7.58% to ¥3,276,590.07[61]. Shareholder and Capital Structure - The company distributed a total cash dividend of RMB 38,780,280.00, with a stock increase of 10 shares for every 10 shares held, raising the total share capital to 111,360,400 shares[9]. - The total share capital after the dividend distribution increased to 111,360,400 shares, reflecting a significant increase in shareholder value[9]. - The actual controllers of the company hold a combined 49.94% of shares, which may influence major decisions and potentially affect minority shareholders' interests[107]. - The largest shareholder, Yan Heping, holds 53,246,000 shares, representing 47.81% of the total shares[128]. - The company has a total of 55,400,400 shares eligible for dividend distribution based on the equity registration date[142]. - The total remuneration paid to directors, supervisors, and senior management during the reporting period amounted to CNY 2.4959 million[154]. Research and Development - The company’s research and development expenses were ¥10,260,570.09, accounting for 6.39% of total revenue, showing a slight decrease of 2.10% from the previous year[55]. - The company is developing a high-temperature glucose oxidase with a stability of over 90% enzyme activity at 70°C, which is expected to enhance product functionality and reduce costs[85]. - A new fermentation enzyme with an activity level exceeding 2300 U/ml has been achieved, aimed at improving product functionality and generating economic benefits[85]. - The company has completed research on a probiotic strain that shows a 95.1% inhibition rate against E. coli and a 91.0% inhibition rate against Staphylococcus aureus, indicating potential for new product development[86]. - The company is exploring the use of plant essential oils as a substitute for antibiotics in animal feed, focusing on the synergistic effects of oregano oil[87]. - The company has optimized the fermentation process for a selected strain of Bacillus, DY9000, which is anticipated to lower production costs[24]. - The company is committed to environmental protection, ensuring compliance with national regulations and effectively controlling waste emissions[97]. Market and Industry Trends - The company aims to expand its market share in feed additives and veterinary medicine, focusing on product quality and cost reduction[41]. - The average price of live pigs for the year was 15.03 yuan/kg, leading to continuous losses for farmers due to oversupply and weak consumption[48]. - The total output value of the national feed industry reached 1,401.83 billion yuan, a year-on-year growth of 6.5%[48]. - The company focused on promoting feed products, achieving a certain growth despite a decline in mixed feed additive sales[45]. - The industry trend emphasizes precision nutrition, which is expected to drive the feed and feed additive sector towards more refined practices[100]. Governance and Compliance - The company has established a comprehensive audit process to ensure the accuracy of financial reporting and compliance with auditing standards[93]. - The company has implemented strict confidentiality procedures for undisclosed insider information to protect investor interests[174]. - The company has maintained a stable governance structure, ensuring that all meetings and decisions comply with legal requirements[171]. - The audit committee of the board confirmed that the financial reports accurately reflect the company's performance and financial status[175]. - The company has engaged a reputable auditing firm to conduct its annual financial audit, ensuring independence and capability[175]. Employee and Management Changes - The total number of employees decreased from 433 to 382, a reduction of approximately 11.8%[156]. - The number of production personnel decreased from 167 to 143, a reduction of 14.4%[155]. - The company emphasizes employee training and development, implementing various training programs for new and existing employees[157]. - New General Manager Yan Lingpeng was appointed in April 2023, succeeding Yan Heping who resigned from the position for personal reasons[151]. - The company has a father-son relationship between Chairman Yan Heping and General Manager Yan Lingpeng[147]. Strategic Goals and Future Plans - The company plans to diversify its product line and reduce reliance on single products to mitigate market risks[105]. - The company aims to develop local feed structures that utilize regional by-products, promoting local economic development[24]. - The company plans to enhance its research and development capabilities through partnerships with industry experts to maintain competitiveness and meet market demands[107]. - The 2024 strategic goals include focusing on key products and increasing customer development efforts to drive sustainable growth[102].

证券代码：871970 证券简称：大禹生物 公告编号：2024-022 山西大禹生物工程股份有限公司 2023 年度独立董事述职报告（宋晓敏） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 本人宋晓敏，作为山西大禹生物工程股份有限公司（以下简称"公司"）的独 立董事，2023 年度严格按照《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司独立董事管理办法》《北京证券交易所上市公司持续监管办法（试行）》 《北京证券交易所股票上市规则（试行）》《北京证券交易所上市公司持续监管指 引第 1 号——独立董事》及《公司章程》等有关法律、法规规定，认真、忠实、 勤勉地履行独立董事职责，发表客观、公正的独立意见，维护公司整体利益，尤 其关注中小投资者的合法权益不受损害。现将本人 2023 年履行独立董事职责情 况汇报如下： 一、会议出席情况 在 2023 年度任职期间，本人积极参加公司召开的董事会并列席股东大会， 认真行使独立董事勤勉尽责的义务，根据相关法律和制度的规定，认真审议所有 议案，并审慎行使表决 ...

证券代码：871970 证券简称：大禹生物 公告编号：2024-008 山西大禹生物工程股份有限公司 第三届董事会第十四次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 4 月 26 日 2.会议召开地点：公司会议室 3.会议召开方式：现场及通讯 4.发出董事会会议通知的时间和方式：2024 年 4 月 16 日以通讯方式发出 5.会议主持人：闫和平 6.会议列席人员：监事及高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召开符合《中华人民共和国公司法》《公司章程》和《董事会议 事规则》的有关规定，所作决议合法有效。 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 董事吴秋生、武晓锋、宋晓敏因工作原因以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于公司 2023 年度董事会工作报告的议案》 1.议案内容： 根据《公司法》等法律法规、规范性文件及《公司章程》等公司 ...

证券代码：871970 证券简称：大禹生物 公告编号：2024-021 山西大禹生物工程股份有限公司 2023 年度独立董事述职报告（武晓锋） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 本人武晓锋，作为山西大禹生物工程股份有限公司（以下简称"公司"）的独 立董事，2023 年度严格按照《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司独立董事管理办法》《北京证券交易所上市公司持续监管办法（试行）》 《北京证券交易所股票上市规则（试行）》《北京证券交易所上市公司持续监管指 引第 1 号——独立董事》及《公司章程》等有关法律、法规规定，认真、忠实、 勤勉地履行独立董事职责，发表客观、公正的独立意见，维护公司整体利益，尤 其关注中小投资者的合法权益不受损害。现将本人 2023 年履行独立董事职责情 况汇报如下： 一、会议出席情况 | 独立董事 | 参加董事会情况 | | | 参加股东大会情况 | | | --- | --- | --- | --- | --- | --- | | 姓名 | 应出 ...

证券代码：871970 证券简称：大禹生物 公告编号：2024-028 | 户名 | 开户行 | 账号 | 余额 | | --- | --- | --- | --- | | 山西大禹生物工程 | 中国邮政储蓄银行 | 914006010003337860 | 13,070,688.54 | | 股份有限公司 | 股份有限公司芮城 | | | | | 县支行 | | | | 山西大禹生物工程 | 山西芮城农村商业 | 654103010300000065690 | 0 | 截至 2023 年 12 月 31 日，募集资金在各银行专项账户的余额具体如下： | 股份有限公司 | 银行股份有限公司 | | | | --- | --- | --- | --- | | 山西大禹生物工程 | 中国银行股份有限 | 140514035159 | 6,881.35 | | 股份有限公司 | 公司芮城支行 | | | | | 合计 | | 13,077,569.89 | 注：上表中公司募集资金账户金额为包含银行存款利息收入、手续费等后的金额。 二、募集资金管理情况 为规范募集资金管理，保护投资者合法权益，根据《北京证券交易所上市 ...

国投证券股份有限公司 关于山西大禹生物工程股份有限公司 2023年度募集资金存放与实际使用情况的专项核查报告 国投证券股份有限公司（以下简称"保荐机构"、"国投证券"）作为山 西大禹生物工程股份有限公司（以下简称"大禹生物"、"发行人"或"公 司"）向不特定合格投资者公开发行股票并在北京证券交易所上市的保荐机构， 根据《证券发行上市保荐业务管理办法》《北京证券交易所股票上市规则（试 行）》《北京证券交易所上市公司持续监管办法（试行）》《北京证券交易所 证券发行上市保荐业务管理细则》等相关法律、法规和规范性文件的规定，对 发行人2023年度募集资金存放与使用情况进行了专项核查，核查情况与意见如 下： 一、募集资金基本情况 公司向不特定合格投资者公开发行股票并在北京证券交易所上市申请于 2022年3月25日经北京证券交易所上市委员会审核同意，并于2022年4月19日经 中国证券监督管理委员会注册（证监许可〔2022〕826号）。 公司本次发行价格为10元/股，发行股数为15,000,000股，实际募集资金总 额为150,000,000.00元，扣除发行费用18,109,528.31元（不含税），实际募集资 金净额 ...

山西大禹生物工程股份有限公司 第三届监事会第十一次会议决议公告 证券代码：871970 证券简称：大禹生物 公告编号：2024-009 4.发出监事会会议通知的时间和方式：2024 年 4 月 16 日 以通讯方式发出 5.会议主持人：赵一霖 6.召开情况合法、合规、合章程性说明： 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 4 月 26 日 2.会议召开地点：公司会议室 3.会议召开方式：现场 本次会议的召开符合《中华人民共和国公司法》、《公司章程》和《监事会议 事规则》的有关规定，所作决议合法有效。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于公司 2023 年度监事会工作报告》议案 1.议案内容： 根据《公司法》等法律法规、规范性文件及《公司章程》等公司内部治理文 件的规定，结合公司 2023 年度监事会的运作情况，公司监事会编制了《2023 年 度监 ...

Financial Performance - Operating revenue for Q1 2024 was CNY 25,100,709.69, representing a 14.13% decrease compared to CNY 29,231,472.90 in Q1 2023[11] - Net profit attributable to shareholders for Q1 2024 was a loss of CNY 4,450,874.05, a 48.02% decline from a loss of CNY 3,006,966.31 in the same period last year[11] - Total operating revenue for Q1 2024 was ¥25,100,709.69, a decrease of 14.5% compared to ¥29,231,472.90 in Q1 2023[36] - Net loss for Q1 2024 was ¥4,450,874.05, compared to a net loss of ¥3,006,966.31 in Q1 2023, representing an increase in loss of 48.2%[37] - Operating profit for Q1 2024 was -¥4,450,874.50, compared to -¥2,996,882.87 in Q1 2023, indicating a worsening of 48.6%[37] Cash Flow - The net cash flow from operating activities for Q1 2024 was a negative CNY 757,836.73, a 90.09% improvement from a negative CNY 7,646,015.20 in Q1 2023[11] - In Q1 2024, the cash inflow from operating activities was CNY 31,482,031.79, a decrease of 15.4% compared to CNY 37,289,256.27 in Q1 2023[42] - The net cash outflow from operating activities was CNY -757,836.73, significantly improved from CNY -7,646,015.20 in the same period last year[42] - Cash outflow for purchasing goods and services was CNY 20,049,683.00, down from CNY 24,093,173.12 in Q1 2023, reflecting a 16.9% reduction[42] - The net cash flow from investing activities was CNY -3,791,310.00, compared to CNY -16,552,276.64 in Q1 2023, indicating a 77% improvement[43] Assets and Liabilities - Total assets as of March 31, 2024, reached CNY 426,032,623, a 0.55% increase from CNY 423,712,742.87 at the end of 2023[11] - The company's total liabilities to assets ratio (consolidated) was 26.56% as of March 31, 2024, compared to 25.11% at the end of 2023[11] - Total liabilities rose to CNY 112,888,257.61, compared to CNY 106,148,658.77, marking an increase of about 6.9%[34] - Current liabilities totaled CNY 87,477,841.92, up from CNY 79,884,493.06, representing an increase of approximately 9.9%[34] - Non-current liabilities decreased slightly to CNY 25,410,415.69 from CNY 26,264,165.71, a decline of about 3.3%[34] Shareholder Information - The total number of ordinary shareholders was 5,168 as of the end of the reporting period[17] - The largest shareholder, Yan Heping, holds 53,246,000 shares, representing 47.81% of total shares[20] - The total shares held by the top ten shareholders amount to 79,632,188, which is 71.51% of the total shares[20] Expenses - Research and development expenses for Q1 2024 were ¥2,226,327.07, slightly down from ¥2,464,389.29 in Q1 2023, a decrease of 9.7%[36] - Sales expenses for Q1 2024 were ¥3,227,327.55, down 18.2% from ¥3,946,838.44 in Q1 2023[36] - Management expenses increased to ¥5,563,313.76 in Q1 2024, up 20.0% from ¥4,636,128.14 in Q1 2023[36] Other Financial Metrics - Non-recurring gains and losses for Q1 2024 totaled CNY 1,239,689.21, with a net amount after tax of CNY 1,228,366.31[14] - Basic and diluted earnings per share for Q1 2024 were both -¥0.04, compared to -¥0.05 in Q1 2023[38] - Credit impairment losses for Q1 2024 were -¥17,948.13, compared to a gain of ¥246,158.06 in Q1 2023, indicating a significant decline[37]

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 本人吴秋生，作为山西大禹生物工程股份有限公司（以下简称"公司"）的独 立董事，2023 年度严格按照《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司独立董事管理办法》《北京证券交易所上市公司持续监管办法（试行）》 《北京证券交易所股票上市规则（试行）》《北京证券交易所上市公司持续监管指 引第 1 号——独立董事》及《公司章程》等有关法律、法规规定，认真、忠实、 勤勉地履行独立董事职责，发表客观、公正的独立意见，维护公司整体利益，尤 其关注中小投资者的合法权益不受损害。现将本人 2023 年履行独立董事职责情 况汇报如下： 一、会议出席情况 证券代码：871970 证券简称：大禹生物 公告编号：2024-020 山西大禹生物工程股份有限公司 2023 年度独立董事述职报告（吴秋生） 在 2023 年度任职期间，本人积极参加公司召开的董事会并列席股东大会， 认真行使独立董事勤勉尽责的义务，根据相关法律和制度的规定，认真审议所有 议案，并审慎行使表决 ...

证券代码：871970 证券简称：大禹生物 公告编号：2024-023 山西大禹生物工程股份有限公司 2023 年度董事会审计委员会履职情况报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 山西大禹生物工程股份有限公司（以下简称"公司"）董事会审计委员会根 据据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立董事管 理办法》《北京证券交易所上市公司持续监管指引第 1 号——独立董事》《公司章 程》《董事会审计委员会议事规则》的规定，对 2023 年度公司审计工作进行了全 面审查，现对审计委员会履职情况报告如下： 一、审计委员会基本情况 2023 年 1 月 1 日至 11 月 9 日，公司第三届董事会审计委员会由独立董事 宋晓敏、武晓锋及董事燕雪野共 3 人组成，主任委员由具有会计专业资格的独立 董事宋晓敏担任。 根据《上市公司独立董事管理办法》相关规定，公司于 2023 年 11 月 9 日召 开第三届董事会第十二次会议审议通过《关于调整第三届董事会审计委员会委员 的议案》。2023 ...